Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPHO-DBH AML 2012 pediatric AML treatment protocol
NL-OMON60711Phase 3Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jan 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin, mitoxantrone, fludarabine, cytarabine, liposomal daunorubicin and 1 more in acute myeloid leukemia (AML) (4 arms), sponsored by Region Västra Götaland. Primary endpoints: MRD negativity after induction course 1, MRD negativity after induction course 2 and 1 more. Started Jan 2014; status: recruiting.
02
Drugs
daunorubicinmitoxantronefludarabinecytarabineliposomal daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60711.